iCAD’s Breast AI Suite is a comprehensive portfolio of technologies for breast cancer detection, density assessment and personalized short-term risk evaluation. Its flagship product, ProFound AI®, became the first AI cancer detection software for 3D mammography to be cleared by the FDA in 2018, and is designed improve accuracy, improve screening effectiveness, and peace of mind. The latest addition to the portfolio, ProFound AI® Risk, is the world's first clinical decision support tool that provides an accurate short-term, breast cancer risk estimation that is truly personalized for each woman, based on age, breast density, and mammographic features. The Breast AI Suite also includes PowerLook® Density Assessment, which offers top performing matching accuracy, as well as consistent, accurate and reliable density categorization for standardized risk-based screening stratification and reporting. With thousands of installations worldwide, iCAD’s breast AI technology is the most widely used in the world. Visit us at www.icadmed.com.